Related Experiment Videos
Venous thrombembolism, thrombophilic defects, combined oral contraception and anticoagulation
Johannes Ott1, Regina Promberger, Ulrike Kaufmann
1Department of Gynaecologic Endocrinology and Reproductive Medicine, Medical University Vienna, Vienna, Austria. johannes.ott@meduniwien.ac.at
Background:
Several genetic polymorphisms increase the risk for venous thrombembolism (VTE). In particular, combined oral contraceptives (COCs) are known to enhance the risk for VTE and are therefore contraindicated.
Case:
We present here the case of a patient with protein S deficiency, who has used COCs together with anticoagulatory therapy (Phenprocoumon) after suffering from deep venous thromboses for 4 years. At the time of her first consultation at our clinic, the ultrasound examination showed a complete involution of her venous thrombosis.
Conclusion:
COCs can be used in patients with thrombogenic mutations and anticoagulatory therapy in individual cases.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis I: Introduction
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis IV: Nursing Management